Amendments to the Specification

Please replace the Sequence Listing in the specification with the Substitute Sequence Listing attached hereto.

Please replace the paragraph on page 5, lines 15-23, with the following amended paragraph:

-- Pharmaceutical formulations of the invention typically comprise an active compound selected from the group consisting of compounds that specifically bind to EMAP II (e.g., an antibody as described above), compounds that inhibit the expression of EMAP II, and EMAP II receptor antagonists; and a pharmaceutically acceptable carrier. Since the N-terminal sequence obtained from the purified EMAP II is encoded by an internal sequence of the EMAP II clone, it was predicted that mature EMAP II (e.g., **SEQ ID NO:5**) results from processing from a larger polypeptide (e.g., **SEQ ID NO:4**) (see Stern et al., U.S. Patent No. 5,641,867, incorporated by reference herein). Any pharmaceutically acceptable carrier may be employed, such as sterile saline solution, sterile water, etc. The active compound is included in the pharmaceutically acceptable carrier in any suitable amount, such as between about .001, .005 or .01 percent by weight to about 10, 20, 50 or 90 percent by weight by weight, or more. --

Please replace the paragraph on page 13, lines 7-13, with the following amended paragraph:

-- Synthesis of antibody. The antibody is generated from the following peptide sequence:

(C)DAFPGEPDKELNP ~~(#252-264)~~ (**SEQ ID NO:1**) (corresponding to amino acids #254-266 (**SEQ ID NO:6**) of **SEQ ID NO:4**)

(C) is a cysteine that is assigned for use in the single point, site-directed conjugation procedure described below, and is not part of the original EMAP II antibody. --